HESTERBIO vs MANKIND: Stock Comparison
MANKIND PHARMA is the larger company by market capitalisation. HESTER BIOSCIENCES shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
HESTERBIO leads 10; MANKIND leads 1 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | HESTERBIO | MANKIND |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | HESTERBIO | MANKIND |
|---|---|---|
| Live Price | ₹2,146.8 | ₹2,275.6 |
| Day Change | -1.08% | -0.43% |
| Volume | 3,399 | 6.5 L |
| 52-Week High | ₹2,683.6 | ₹2,642 |
| 52-Week Low | ₹1,239.3 | ₹1,909.7 |
| Distance from 52W High | -20% | -13.87% |
Valuation
| Metric | HESTERBIO | MANKIND |
|---|---|---|
| Market Cap | ₹1,814 Cr | ₹94,042 Cr |
| P/E Ratio | 13.32x | 45.88x |
| P/B Ratio | 5.04x | 5.77x |
| EPS | ₹114 | ₹13.9 |
| Book Value | ₹432.34 | ₹401 |
| Dividend Yield | 0.51% | 0% |
Growth
| Metric | HESTERBIO | MANKIND |
|---|---|---|
| Revenue Growth (TTM YoY) | 38.2% | 11.8% |
| EPS Growth (TTM YoY) | 968.7% | 31.7% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | HESTERBIO | MANKIND |
|---|---|---|
| ROE | 13.53% | 12.41% |
| ROCE | 12.67% | 11.87% |
| Net Margin | 16.73% | 13.34% |
| Operating Margin | 26.31% | 27.68% |
| Debt to Equity | 0.19x | 0.34x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | HESTERBIO | MANKIND |
|---|---|---|
| Promoter Holding | 44.28% | 72.62%▼ 0.01 pp |
| FII Holding | 0.31% | 9.37%▼ 0.08 pp |
| DII Holding | 0.08%▲ 0.08 pp | 15.56%▲ 0.17 pp |
| Public Holding | 55.33%▲ 9.38 pp | 2.45%▼ 0.08 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: HESTER BIOSCIENCES and MANKIND PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.